Evidence map›Paper›PMID 41187138›Full record

ArticlePLoS medicine2025

Financial risk protection from vaccines in 52 Gavi-eligible low- and middle-income countries: A modeling study.

Boshen Jiao, Ryoko Sato, Joshua Mak, Bryan Patenaude, Margaret de Villiers, Aniruddha Deshpande, Ivane Gamkrelidze, Katy A M Gaythorpe, Timothy B Hallett, Mark Jit and 9 more

Abstract read
In one paragraph

Article in PLoS medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Boshen JiaoLeonard D. Schaeffer Center for Health Policy and Economics, University of Southern California, Los Angeles, California, United States of America.
Ryoko SatoDepartment of Global Health and Population, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, United States of America.
Joshua MakDepartment of Global Health and Population, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, United States of America.
Bryan PatenaudeDepartment of International Health, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, United States of America.ORCID https://orcid.org/0000-0002-5180-3626
Margaret de VilliersMRC Centre for Global Infectious Disease Analysis, School of Public Health, Imperial College London, London, United Kingdom.
Aniruddha DeshpandeDepartment of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, Georgia, United States of America.ORCID https://orcid.org/0000-0003-0427-241X
Ivane GamkrelidzeCDA Foundation, Lafayette, Colorado, United States of America.ORCID https://orcid.org/0000-0003-3843-670X
Katy A M GaythorpeMRC Centre for Global Infectious Disease Analysis, School of Public Health, Imperial College London, London, United Kingdom.ORCID https://orcid.org/0000-0003-3734-9081
Timothy B HallettMRC Centre for Global Infectious Disease Analysis, School of Public Health, Imperial College London, London, United Kingdom.ORCID https://orcid.org/0000-0002-9681-0424
Mark JitDepartment of Infectious Disease Epidemiology and Dynamics, London School of Hygiene and Tropical Medicine, London, United Kingdom.ORCID https://orcid.org/0000-0001-6658-8255
Xiang LiMRC Centre for Global Infectious Disease Analysis, School of Public Health, Imperial College London, London, United Kingdom.
Benjamin LopmanDepartment of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, Georgia, United States of America.ORCID https://orcid.org/0000-0002-9238-0068
Shevanthi NayagamMRC Centre for Global Infectious Disease Analysis, School of Public Health, Imperial College London, London, United Kingdom.
Devin Razavi-ShearerCDA Foundation, Lafayette, Colorado, United States of America.
Yvonne TamDepartment of International Health, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, United States of America.
Kim H WoodruffMRC Centre for Global Infectious Disease Analysis, School of Public Health, Imperial College London, London, United Kingdom.ORCID https://orcid.org/0000-0003-4618-8267
Daniel HoganGavi, the Vaccine Alliance, Geneva, Switzerland.
Tewodaj MengistuGavi, the Vaccine Alliance, Geneva, Switzerland.ORCID https://orcid.org/0000-0003-3475-3599
Stéphane VerguetDepartment of Global Health and Population, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, United States of America.ORCID https://orcid.org/0000-0003-4128-0849

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPoverty alleviation is a major global development goal. Vaccines have the potential to provide financial risk protection (FRP) by preventing illnesses and associated healthcare costs. We estimate the lifetime FRP benefits generated by major vaccines among individuals vaccinated between 2000 and 2030 in low- and middle-income countries (LMICs). METHODS AND

findingsWe developed a microsimulation model to quantify the number of cases of catastrophic health expenditure (CHE) averted by a range of vaccines in 52 Gavi-eligible countries, stratified by wealth quintile. Vaccines protecting against five pathogens were considered, i.e., hepatitis B (routine and birth dose vaccine), Haemophilus influenzae type B, rotavirus, measles (routine and supplementary campaign vaccine), and Streptococcus pneumoniae. Model inputs were obtained from secondary data sources, including infection reduction rates under various immunization coverage scenarios, out-of-pocket health expenditures, transportation costs, wage losses, and healthcare utilization associated with disease treatment and consumption expenditures. CHE cases were defined as exceeding 10% of annual consumption, with sensitivity analyses conducted using thresholds of 25% and 40%, as well as impoverishing health expenditures were estimated. All vaccines, singly and collectively, showed a large impact on FRP and could avert ~200 million CHE cases across 52 Gavi-eligible countries from 2000 to 2030. Importantly, about half of all CHE cases were prevented among the poorest quintiles. When evaluated at a 10% threshold for CHE, the first dose of measles vaccine stood out in averting around 1,400 CHE cases per 10,000 vaccinated individuals in the poorest quintile, that is a total of 44 million CHE cases averted. A key limitation is the assumption of uniform disease risks in the absence of vaccination across quintiles, which may underestimate benefits for poorer groups.

conclusionsVaccines can provide substantial FRP benefits, particularly among the most disadvantaged populations. Sustained investments to ensure vulnerable populations receive vaccinations in LMICs can therefore not only improve health outcomes but also contribute to poverty reduction.

Indexed as

Developing CountriesImmunization ProgramsModels, EconomicVaccinationVaccinesHealth ExpendituresHumansPovertyVaccines

Identifiers

PMID41187138
PMCPMC12585062

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.